Psychedelics – News and Features

Researchers from the Millenium Research Institute and the University of Cincinnati have utilised Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for the testing of illicit drugs.

Pharmatek Laboratories, Inc. have announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities. The company has purchased two roller compactors, a pilot-scale. Both machines have been integrated into Pharmatek’s GMP facility and are ready for GMP manufacturing.

The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products with clinical testing.

An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.

EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.

Randox are working with the international racing laboratories to maintain the integrity of racing, to make certain animals are winning races on their own natural merits and to ensure the safety of the animals and jockeys is maintained.

The new protocol exploits the company’s know-how and capabilities in development and manufacture of iv dosage forms and their efficient integration into clinical studies.

The Company has announced record growth, new medical director and pediatric board member.

The milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose DPI technology.

The EUMAPP consortium presented preliminary results from the 30-month, €2m project at the EUFEPS Conference.